一分钟看懂
这是一项关于头颈部肿瘤的II 期研究，登记的药物或干预包括Penpulimab injection；cisplatin；albumin-paclitaxel，当前状态为研究进行中，已停止招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Penpulimab injection；cisplatin；albumin-paclitaxel · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为不限性别，年龄18岁至75岁；以下仅摘录4项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Patients voluntarily joined the study, signed the informed consent, and had good compliance;
- * Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-1;
- * Patients with untreated head and neck squamous cell carcinoma who were pathologically confirmed and determined to be suitable for surgical treatment were classified as stage III, IVa according to AJCC (8th Edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
- * Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06081673；登记信息更新于 2026-09-30；本站同步于 2026-10-08。